Pharmacologic Category
Anticonvulsant, Miscellaneous; GABA Analog
Dosing: Adult
Note: When discontinuing, taper off gradually over at least 1 week.
Cough, chronic refractory (alternative agent) (off-label use): Immediate release: Oral: Initial: 75 mg once daily; may increase gradually over the first week in increments of 75 mg/day based on response and tolerability up to a maximum of 300 mg/day in 3 divided doses (eg, 75 mg in morning and midday with 150 mg in the evening) (Vertigan 2016).
Fibromyalgia (alternative agent): Note: For patients who do not respond to or tolerate preferred agents (Goldenberg 2018).
Immediate release: Oral: Initial: 75 mg twice daily; may increase to 150 mg twice daily within 1 week based on response and tolerability; maximum dose: 450 mg/day (manufacturer's labeling). Note: Some experts suggest lower initial doses of 25 to 50 mg at bedtime; some patients may respond to maintenance doses <300 mg/day (Goldenberg 2018).
Generalized anxiety disorder (alternative agent) (off-label use): Note: Monotherapy or adjunctive therapy for patients who do not tolerate or respond to preferred agents (BAP [Baldwin 2014]; Craske 2018).
Immediate release: Oral: Initial: 150 mg/day in 2 to 3 divided doses; may increase based on response and tolerability at weekly intervals in increments of 150 mg/day up to a usual dose of 300 mg/day. May further increase up to 600 mg/day (Kasper 2014; WFSBP [Bandelow 2008]); however, additional benefit of doses >300 mg/day is uncertain (Lydiard 2010). Note: Some experts suggest a lower initial dose of 50 mg/day (Bystritsky 2018).
Neuropathic pain:
General dosing recommendations: Immediate release: Oral: Initial: 25 to 150 mg/day once daily or in 2 divided doses; may increase in increments of 25 to 150 mg/day at intervals ≥1 week based on response and tolerability up to a usual dose of 300 to 600 mg/day in 2 divided doses (CPS [Moulin 2014]; IASP [Finnerup 2015]).
Critically ill ICU patients (off-label use): Oral: Initial: 75 mg once or twice daily in combination with opioids; maintenance dose: 150 to 300 mg twice daily (SCCM [Devlin 2018]; Tietze 2019).
Diabetic neuropathy:
Immediate release: Oral: Initial: 25 to 75 mg/day once daily or in 2 to 3 divided doses; may increase within 1 week based on response and tolerability up to a maximum dose of 300 to 450 mg/day (ADA [Pop-Busui 2017]; Feldman 2018). Higher doses up to 600 mg/day may have greater adverse effects without additional benefit (Arnold 2017).
Extended release: Oral: Initial: 165 mg once daily; may increase within 1 week based on response and tolerability up to maximum dose of 330 mg once daily.
Postherpetic neuralgia:
Immediate release: Oral: Initial: 150 mg/day in divided doses (75 mg twice daily or 50 mg 3 times daily); may increase to 300 mg/day within 1 week based on response and tolerability; after 2 to 4 weeks, may further increase up to the maximum dose of 600 mg/day.
Extended release: Oral: Initial: 165 mg once daily; may increase to 330 mg once daily within 1 week based on response and tolerability; after 2 to 4 weeks, may further increase up to the maximum dose of 660 mg/day.
Spinal cord injury-associated neuropathic pain: Immediate release: Oral: Initial: 75 mg twice daily; may increase within 1 week based on response and tolerability to 150 mg twice daily; after 2 to 3 weeks, may further increase up to a maximum of 600 mg/day.
Postoperative pain (off-label use): Immediate release: Oral: 75 to 300 mg as a single dose, 1 to 2 hours prior to surgery as part of a multimodal analgesia regimen. The use of multiple doses has not been found to provide additional benefit (APS [Chou 2016]; Mishriky 2015).
Pruritus, chronic (alternative agent) (off-label use): Note: For patients with pruritus resistant to preferred therapies (Matsuda 2016; Weisshaar 2012).
Neuropathic (eg, brachioradial pruritus, notalgia paresthetica) or malignancy related: Based on limited data: Immediate release: Oral: Initial: 75 mg twice daily; may increase based on response and tolerability up to 150 to 300 mg/day in 2 to 3 divided doses (Atis 2017; Fazio 2018; Matsuda 2016; Vestita 2016). Higher doses up to 600 mg/day have been used in oncology populations (Dalal 2018).
Uremic: Immediate release: Oral: Variable dosing has been used and includes: 50 mg every other day given after dialysis on hemodialysis days (Foroutan 2017) or 25 mg daily (Kobrin 2018), each increased based on response and tolerability to 50 or 75 mg daily; 75 mg twice weekly given after dialysis on hemodialysis days also appears effective (Yue 2015).
Restless legs syndrome (off-label use): Immediate release: Oral: Initial: 50 to 75 mg once daily, 1 to 3 hours before bedtime; gradually increase (eg, in increments of 75 to 150 mg) every 5 to 7 days based on response and tolerability to a usual effective dose of 150 to 450 mg/day (Allen 2010; Allen 2014; Garcia-Borreguero 2014).
Seizures, focal (partial) onset (adjunctive therapy with other anticonvulsants): Immediate release: Oral: Initial: 150 mg/day in 2 or 3 divided doses; may increase based on response and tolerability at weekly intervals up to a maximum dose of 600 mg/day.
Social anxiety disorder (alternative agent) (off-label use): Note: Monotherapy or adjunctive therapy for patients who do not tolerate or respond to preferred agents (Stein 2018). Immediate release: Oral: Initial: 100 mg 3 times daily; may increase over 1 week in increments of 150 mg/day based on response and tolerability up to 600 mg/day (Feltner 2011; Greist 2011; Pande 2004).
Vasomotor symptoms associated with menopause (alternative agent) (off-label use): Note: Used as a nonhormonal alternative in patients unable or unwilling to take preferred agents (Stuenkel 2015). Some experts prefer gabapentin over pregabalin as an alternative agent because of greater available evidence (Santen 2018).
Immediate release: Oral: Initial: 50 mg once daily at bedtime; may increase at weekly intervals based on response and tolerability to 50 mg twice daily, and then up to 75 mg twice daily; may further increase up to 150 mg twice daily (Loprinzi 2010).
Dosing conversion from immediate-release oral formulations to extended-release oral formulation: Note: On the day of the switch, administer morning dose of immediate-release product as prescribed, and initiate extended-release therapy after the evening meal.
Immediate-release total daily dose of 75 mg is equivalent to extended-release dose of 82.5 mg once daily
Immediate-release total daily dose of 150 mg is equivalent to extended-release dose of 165 mg once daily
Immediate-release total daily dose of 225 mg is equivalent to extended-release dose of 247.5 mg once daily
Immediate-release total daily dose of 300 mg is equivalent to extended-release dose of 330 mg once daily
Immediate-release total daily dose of 450 mg is equivalent to extended-release dose of 495 mg once daily
Immediate-release total daily dose of 600 mg is equivalent to extended-release dose of 660 mg once daily
Discontinuation of therapy: In patients receiving pregabalin chronically, unless safety concerns require a more rapid withdrawal, pregabalin should be withdrawn gradually over ≥1 week to minimize the potential of increased seizure frequency (in patients with epilepsy) or other withdrawal symptoms (eg, agitation, confusion, delirium, delusions, GI symptoms, mood changes, sweating, withdrawal seizures) (Bonnet 2017; "Gabapentin and Pregabalin" 2012).
* See Dosage and Administration in AHFS Essentials for additional information.
Dosing: Geriatric
Refer to adult dosing; use with caution. In the management of restless legs syndrome, a starting dose of 50 mg once daily in patients >65 years has been recommended (Garcia-Borreguero 2016).
Dosing: Renal Impairment: Adult
Immediate release: Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl ≥60 mL/minute). For example, if the indication-specific daily dose is 450 mg daily for normal renal function, the daily dose should be reduced to 225 mg daily (in 2 to 3 divided doses) for a creatinine clearance of 30 to 60 mL/minute (see table).
Immediate-Release Pregabalin Renal Impairment Dosing
CrCl
(mL/minute)
Total Pregabalin Daily Dose
(mg/day)
Dosing Frequency
Hemodialysis: Dialyzable (~50%); supplementary dosage posthemodialysis (as a single additional dose):
25 mg/day schedule: Single supplementary dose of 25 mg or 50 mg
25 to 50 mg/day schedule: Single supplementary dose of 50 mg or 75 mg
50 to 75 mg/day schedule: Single supplementary dose of 75 mg or 100 mg
75 mg/day schedule: Single supplementary dose of 100 mg or 150 mg
≥60 (normal renal function)
150
300
450
600
2 to 3 divided doses
30 to 60
75
150
225
300
2 to 3 divided doses
15 to 30
25 to 50
75
100 to 150
150
1 to 2 divided doses
<15
25
25 to 50
50 to 75
75
Single daily dose
Extended release: Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl ≥60 mL/minute). For example, if the indication-specific daily dose is 495 mg once daily for normal renal function, the daily dose should be reduced to 247.5 mg once daily for a creatinine clearance of 30 to 60 mL/minute (see table).
Extended-Release Pregabalin Renal Impairment Dosing
CrCl (mL/minute)
Total Pregabalin Daily Dose (mg/day)
Dosing Frequency
≥60 (normal renal function)
165
330
495
660
Once daily
30 to 60
82.5
165
247.5
330
Once daily
<30
Extended-release product not recommended; use immediate-release product
Hemodialysis
Dosing: Hepatic Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling. However, no adjustment is expected since undergoes minimal hepatic metabolism.
Dosing: Pediatric
Note: When discontinuing, taper off gradually over at least 1 week.
Seizures, partial onset; adjunctive therapy: Immediate release:
Infants and Children <4 years weighing <30 kg: Oral: Initial dose: 3.5 mg/kg/day in 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 14 mg/kg/day.
Children ≥4 years and Adolescents <17 years:
<30 kg: Oral: Initial dose: 3.5 mg/kg/day in 2 or 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 14 mg/kg/day.
≥30 kg: Oral: Initial dose: 2.5 mg/kg/day in 2 or 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 10 mg/kg/day not to exceed 600 mg/day.
Adolescents ≥17 years: Oral: Initial dose: 150 mg daily in 2 or 3 divided doses; may be increased weekly based on tolerability and effect; maximum daily dose: 600 mg/day.
Fibromyalgia: Limited data available: Immediate release: Children ≥12 years and Adolescents: Oral: Initial: 37.5 mg twice daily for 1 week, then titrate based on clinical response and tolerability to 150 to 450 mg/day in 2 divided doses; maximum daily dose: 450 mg/day. Dosing based on a multi-center, double-blind, placebo-controlled trial (15 weeks) and secondary open-label continuation trial (6 months) (n=107; pregabalin n=54; age range: 12 to 17 years); total daily doses were titrated weekly to an individually optimized dose of 150 mg/day, 300 mg/day, or 450 mg/day; maximum daily dose: 450 mg/day; mean dose during maintenance phase of double-blind study was 244.5 mg/day and in the open label trial it was 254.3 mg/day. Although the primary endpoint of change in mean pain scores from baseline to week 15 was not statistically significant, there was a trend toward improvement in the pregabalin group. Change in weekly mean pain scores was significantly greater with pregabalin compared to placebo for 10 of the 15 weeks; the patient global impression of change was also significantly improved in patients receiving pregabalin (53.1%) compared to placebo (29.5%). The authors reported a large placebo effect, particularly at non-US study centers; however, significance of this is unknown (Arnold 2016).
Dosing: Renal Impairment: Pediatric
Immediate release: There are no pediatric-specific dosage adjustments provided in manufacturer's labeling (has not been studied); based on experience in adult patients, dosing adjustment may be necessary.
Dosing: Hepatic Impairment: Pediatric
Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; however, no adjustment is expected since pregabalin undergoes minimal hepatic metabolism.
Calculations
Use: Labeled Indications
Fibromyalgia (immediate release only): Management of fibromyalgia
Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release): Management of neuropathic pain associated with diabetic peripheral neuropathy
Neuropathic pain associated with spinal cord injury (immediate release only): Management of neuropathic pain associated with spinal cord injury
Postherpetic neuralgia (immediate release and extended release): Management of postherpetic neuralgia
Seizures, focal (partial) onset (immediate release only): Adjunctive therapy in patients ≥1 month of age with focal onset (partial-onset) seizures
* See Uses in AHFS Essentials for additional information.
Use: Off-Label: Adult
Cough, chronic refractoryLevel of Evidence [C]
Data from a limited number of patients in a controlled trial suggest that pregabalin in combination with speech pathology therapy may be beneficial for the treatment of refractory chronic cough Ref. Access Full Off-Label Monograph
Generalized anxiety disorderLevel of Evidence [B, G]
Data from several meta-analyses support the use of pregabalin in the treatment of generalized anxiety disorder Ref.
Based on the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorders and Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress, and obsessive-compulsive disorders, pregabalin is effective and recommended as a first-line agent in the management of generalized anxiety disorder. The British Association for Psychopharmacology guidelines for evidence-based pharmacological treatment of anxiety disorders, posttraumatic stress disorder, and obsessive-compulsive disorder recommend pregabalin as an alternative initial treatment if SSRIs are considered unsuitable and for augmentation after nonresponse to initial SSRI or SNRI treatment. Access Full Off-Label Monograph
Neuropathic pain, critically ill patientsLevel of Evidence [G]
The Society of Critical Care Medicine Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU suggest pregabalin in combination with opioids is recommended for the management of neuropathic pain in ICU patients Ref.
Postoperative pain (as a component of multimodal analgesia in select patients)Level of Evidence [B]
Data from several meta-analyses support the use of preemptive doses of pregabalin to decrease postoperative pain, opioid use, and nausea and vomiting Ref. Access Full Off-Label Monograph
Pruritus, neuropathic or malignancy relatedLevel of Evidence [C]
Data from a limited number of patients studied suggest that pregabalin may be beneficial for the treatment of chronic neuropathic or malignancy-related pruritus Ref. Access Full Off-Label Monograph
Pruritus, uremicLevel of Evidence [B, G]
Data from several randomized, controlled trials support the use of pregabalin in the treatment of chronic uremic pruritus in dialysis patients Ref.
Based on the European Dermatology Forum and European Academy of Dermatology and Venerology guidelines on chronic pruritus, pregabalin is recommended in the management of chronic kidney disease-associated pruritus Ref. Access Full Off-Label Monograph
Restless legs syndromeLevel of Evidence [B, G]
Data from randomized, double-blind, placebo-controlled studies support the use of pregabalin in the treatment of moderate to severe primary restless legs syndrome (RLS) with predominant evening symptoms Ref.
Based on American Academy of Neurology guidelines and guidelines from the International Restless Legs Syndrome Study Group for the long-term treatment of RLS, pregabalin is effective and recommended in the management of primary RLS Ref
Based on the International Restless Legs Syndrome Study Group (IRLSSG), European Restless Legs Syndrome Study Group (EURLSSG), and Restless Legs Syndrome Foundation guidelines for the prevention and treatment of dopaminergic augmentation in RLS, alpha-2-delta ligands (eg, pregabalin), are effective and should be considered for the initial treatment of patients with RLS due to their minimal risk of augmentation. Additionally, patients who experience augmentation on dopaminergic agents may benefit from a switch to alpha-2-delta ligands (eg, pregabalin). Access Full Off-Label Monograph
Social anxiety disorderLevel of Evidence [B]
Data from 2 double-blind, placebo-controlled, fixed-dose studies and a relapse prevention study support the use of pregabalin in the treatment of social anxiety disorder Ref.
Vasomotor symptoms associated with menopauseLevel of Evidence [B, G]
Data from a randomized, double-blind, placebo-controlled trial support the use of pregabalin in the treatment of vasomotor symptoms (eg, hot flashes) associated with menopause, including women previously treated for breast cancer Ref.
Based on the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause, the Endocrine Society guideline on the treatment of symptoms of menopause, and the North American Menopause Society (NAMS) position statement on nonhormonal management of menopause-associated vasomotor symptoms, pregabalin is an effective and recommended alternative for the management of vasomotor symptoms associated with menopause in patients with contraindications to hormonal therapy or who prefer not to use hormonal therapy. Access Full Off-Label Monograph
Level of Evidence Definitions
Level of Evidence Scale
Class and Related Monographs
Comparative Efficacy
Clinical Practice Guidelines
Critical Care:
ACCM/SCCM, "Clinical Practice Guidelines for the Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU,” August 2018
Menopause:
Endocrine Society (ES), Treatment of Symptoms of the Menopause, 2015
North American Menopause Society (NAMS), Nonhormonal management of menopause-associated vasomotor symptoms, 2015
Neuropathic Pain:
American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation, "Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy," April 2011
American Diabetes Association, “Diabetic Neuropathy: A Position Statement by the American Diabetes Association,” 2017
European Federation of Neurological Societies (EFNS), “EFNS guidelines on the pharmacological treatment of neuropathic pain, 2010 revision,” 2010
International Association for the Study of Pain,” Pharmacotherapy for Neuropathic Pain in Adults: Systematic Review, Meta-analysis and Updated NeuPSIG Recommendations,” 2015
National Institute for Health and Care Excellence, “Neuropathic Pain in Adults: Pharmacological Management in Non-specialist Settings,” 2013
Toronto Diabetic Neuropathy Expert Group, “Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments,” 2010
Restless Legs Syndrome:
American Academy of Neurology, “Practice Guideline Summary: Treatment of Restless Legs Syndrome in Adults,” November 2016
American Academy of Sleep Medicine, "The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012: Practice parameters with an evidence-based systematic review and meta-analysis," 2012
European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society, “European guidelines on management of restless legs syndrome: Report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society,” November 2012
International Restless Legs Syndrome Study Group (IRLSSG), European Restless Legs Syndrome Study Group (EURLSSG), and Restless Legs Syndrome Foundation, “Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG and the RLS Foundation, “ May 2016
Seizure Disorders:
American Academy of Neurology and American Epilepsy Society, “Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy,” 2018
American Academy of Neurology and American Epilepsy Society, “Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy, “ 2018
Administration: Oral
Immediate release: May be administered with or without food.
Extended release: Administer once daily after an evening meal; swallow whole, do not split, crush, or chew. A missed dose should be taken before bedtime following a snack. If missed before bedtime, administer in the morning with a meal. If missed in the morning, wait until the evening meal to take the next scheduled dose.
Administration: Pediatric
Oral: Immediate release: May be administered with or without food.
Storage/Stability
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Medication Patient Education with HCAHPS Considerations
What is this drug used for?
• It is used to help control certain kinds of seizures, to treat painful nerve diseases, and to treat fibromyalgia. It may be given to you for other reasons. Talk with the doctor.
Frequently reported side effects of this drug
• Nose irritation
• Throat irritation
• Trouble focusing
• Headache
• Dry mouth
• Loss of strength and energy
• Constipation
• Lack of appetite
• Joint pain
• Nausea
Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:
• Swelling in your throat
• Depression like thoughts of suicide, anxiety, agitation, irritability, panic attacks, mood changes, behavioral changes, or confusion
• Vision changes
• Muscle pain
• Muscle weakness
• Seizures
• Bruising
• Bleeding
• Change in balance
• Confusion
• Tremors
• Trouble breathing
• Slow breathing
• Shallow breathing
• Blue/gray skin discoloration
• Trouble with memory
• Shortness of breath
• Excessive weight gain
• Swelling of arms or legs
• Fast heartbeat
• Abnormal heartbeat
• Chills
• Sore throat
• Skin sores
• Trouble speaking
• Trouble sleeping
• Abnormal gait
• Feeling high
• Twitching
• Severe fatigue
• Severe dizziness
• Passing out
• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.
Medication Safety Issues
Sound-alike/look-alike issues:
Other safety concerns:
Medication Guide and/or Vaccine Information Statement (VIS)
An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:
Lyrica: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021446s036,022488s014lbl.pdf#page=56
Lyrica CR: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209501s000lbl.pdf#page=29
Contraindications
Hypersensitivity (eg, angioedema) to pregabalin or any component of the formulation
Warnings/Precautions
Concerns related to adverse effects:
• Angioedema: Angioedema has been reported during initial and chronic treatment; may be life-threatening. Symptoms reported include facial, mouth (tongue, lips, and gums), and neck (throat and larynx) swelling. Use with caution in patients with a history of angioedema episodes. Concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk. Discontinue treatment immediately if angioedema occurs.
• CNS effects: Dizziness and somnolence are commonly reported; effects generally occur shortly after initiation and occur more frequently at higher doses. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Hematologic effects: May decrease platelet count. Severe thrombocytopenia is extremely rare.
• Hypersensitivity: Hypersensitivity reactions, including skin redness, blistering, hives, rash, dyspnea, and wheezing have been reported shortly after initiation of treatment; discontinue treatment if hypersensitivity occurs.
• Peripheral edema: Use may cause peripheral edema; use with caution in patients with heart failure (NYHA Class III or IV) due to limited data in this patient population. In addition, effect on weight gain/edema may be additive with the thiazolidinedione class of antidiabetic agents; use caution when coadministering these agents, particularly in patients with prior cardiovascular disease.
• PR interval: May cause mild prolongation of PR interval. Clinical significance unknown.
• Rhabdomyolysis: Has been associated with increases in creatine kinase and rare cases of rhabdomyolysis; patients should be instructed to notify their prescriber if unexplained muscle pain, tenderness, or weakness, particularly if fever and/or malaise are associated with these symptoms. Discontinue treatment if myopathy is suspected or diagnosed or if markedly elevated creatine kinase levels occur.
• Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.
• Visual disturbances: Blurred vision, decreased acuity and visual field changes have been associated with therapy; patients should be instructed to notify their physician if these effects are noted.
• Weight gain: Use may cause weight gain; weight gain generally associated with dose and duration (average weight gain was 5.2 kg for diabetic patients receiving pregabalin for ≥2 years); weight gain was not limited to patients with edema and did not appear to be associated with baseline BMI, gender, age, or loss of glycemic control in diabetic patients.
Disease-related concerns:
• Cardiovascular disease: Use with caution in patients with severe cardiovascular disease, including heart failure; weight gain and/or peripheral edema may occur. In a scientific statement from the American Heart Association, pregabalin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: minor to moderate) (AHA [Page 2016]).
• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.
• Substance abuse: Use with caution in patients with a history of substance abuse; potential for behavioral dependence in this population exists (Bonnet 2017).
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Other warnings/precautions:
• Tumorigenic potential: Increased incidence of hemangiosarcoma noted in animal studies; significance of these findings in humans is unknown.
• Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually unless safety concerns require a more rapid withdrawal. Tapering over at least 1 week is recommended. Abrupt discontinuation with pregabalin has been associated with anxiety, diarrhea, headache, hyperhidrosis, insomnia, and nausea.
* See Cautions in AHFS Essentials for additional information.
Geriatric Considerations
In clinical studies, no differences in safety and efficacy were noted between elderly. Since pregabalin is primarily excreted renally, dosage adjustment, based on CrCl, is necessary.
Pregnancy Considerations
Pregabalin crosses the placenta (Ohman 2011). Studies which evaluated neonatal outcomes following pregabalin exposure during pregnancy are limited (Mostacci 2017; Patorno 2017; Veiby 2014; Winterfeld 2016). Pregabalin has been evaluated as an adjuvant pain medication following cesarean section and pregnancy termination (El Kenany 2016; Lavand'homme 2010).
In a study conducted in males, pregabalin was found to temporarily decrease mean sperm concentrations; no effects on sperm morphology or motility were observed. Concentrations increased after pregabalin was discontinued. The clinical relevance of this is not known.
Data collection to monitor pregnancy and infant outcomes following exposure to pregabalin is ongoing. Patients exposed to pregabalin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.
Breast-Feeding Considerations
Pregabalin is present in breast milk.
The relative infant dose (RID) of pregabalin is ~7% when calculated using an average breast milk concentration compared to a weight-adjusted maternal dose of 300 mg/day.
In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).
The RID of pregabalin was calculated using an average milk concentration of 2.05 mcg/mL, providing an estimated daily infant dose via breast milk of 0.31 mg/kg/day. This milk concentration was obtained following maternal administration of pregabalin 150 mg orally twice daily for 4 doses. The study included 10 women who were ~37 weeks' postpartum (range: 15 to 81 weeks). Infants were not breastfed during the study period. Peak concentrations in breast milk were generally lower than those in the maternal plasma (Lockwood 2016). A slightly higher RID of ~8% was noted in a case report (Ohman 2011). Poor latching on, lasting ~8 hours, was observed in three infants immediately postpartum following a single maternal dose of pregabalin for pain during cesarean delivery (El Kenany 2016). Breastfeeding is not recommended by the manufacturer.
Briggs' Drugs in Pregnancy & Lactation
Adverse Reactions
As reported with adult patients, unless otherwise noted.
>10%:
Cardiovascular: Peripheral edema (4% to 16%)
Central nervous system: Dizziness (3% to 45%), drowsiness (≤36%; infants, children, and adolescents: 13% to 26%), headache (2% to 14%), fatigue (4% to 11%)
Endocrine & metabolic: Weight gain (2% to 14%)
Gastrointestinal: Xerostomia (≤15%)
Ophthalmic: Visual field loss (13%), blurred vision (≤12%)
1% to 10%:
Cardiovascular: Edema (≤8%), facial edema (1% to 3%), chest pain (2%), hypertension (2%), hypotension (2%)
Central nervous system: Ataxia (2% to 9%), balance impairment (2% to 9%), abnormal gait (1% to 8%), euphoria (2% to 7%), confusion (1% to 7%), disturbance in attention (4% to 6%), abnormality in thinking (1% to 6%), neuropathy (5%), pain (3% to 5%), myasthenia (1% to 5%), insomnia (4%), amnesia (1% to 4%), memory impairment (1% to 4%), vertigo (1% to 4%), hypoesthesia (2% to 3%), feeling abnormal (1% to 3%), speech disturbance (1% to 3%), anxiety (2%), paresthesia (2%), disorientation (1% to 2%), intoxicated feeling (1% to 2%), lethargy (1% to 2%), anorgasmia (≥1%), depersonalization (≥1%), hypertonia (≥1%), sedated state (≥1%), stupor (≥1%), twitching (≥1%; includes myokymia), nervousness (1%)
Dermatologic: Pressure ulcer (3%), ecchymoses (≥1%), pruritus (≥1%), contact dermatitis (1%)
Endocrine & metabolic: Fluid retention (2% to 3%), hypoglycemia (2% to 3%), decreased libido (≥1%)
Gastrointestinal: Constipation (3% to 10%), increased appetite (3% to 10%), nausea (3% to 5%), sialorrhea (children and adolescents: 1% to 4%), flatulence (2% to 3%), vomiting (1% to 3%), abdominal distension (2%), abdominal pain (≥1%), gastroenteritis (≥1%), diarrhea (1%), viral gastroenteritis (≤1%)
Genitourinary: Urinary incontinence (1% to 3%), impotence (≥1%), urinary frequency (≥1%), erectile dysfunction (≤1%), urinary tract infection (1%)
Hematologic & oncologic: Thrombocytopenia (3%)
Hepatic: Increased serum alanine aminotransferase (≤1%), increased serum aspartate aminotransferase (≤1%)
Hypersensitivity: Hypersensitivity reaction (≥1%)
Infection: Infection (6% to 8%), viral infection (infants and children: 6%)
Neuromuscular & skeletal: Asthenia (4% to 7%), arthralgia (1% to 6%), muscle spasm (4%), back pain (1% to 4%), limb pain (3%), neck pain (3%), increased creatine phosphokinase in blood specimen (2% to 3%), tremor (1% to 3%), joint swelling (≤2%), lower limb cramp (≥1%), myalgia (≥1%)
Ophthalmic: Decreased visual acuity (7%), visual disturbance (1% to 5%), diplopia (≤4%), eye disease (1% to 2%), conjunctivitis (≥1%), nystagmus disorder (≥1%)
Otic: Otitis media (≥1%), tinnitus (≥1%)
Respiratory: Pneumonia (infants and children: 1% to 9%; adults: <1%), nasopharyngitis (1% to 8%), sinusitis (≤7%), bronchitis (3%), pharyngolaryngeal pain (3%), dyspnea (2%), flu-like symptoms (2%), cough (1%), respiratory tract infection (1%)
Miscellaneous: Accidental injury (3% to 6%), fever (≥1%)
Frequency not defined: Cardiovascular: Prolongation P-R interval on ECG
<1%, postmarketing, and/or case reports: Abnormal dreams, abscess, accommodation disturbance, acute renal failure, ageusia, agitation, albuminuria, alopecia, altered sense of smell, amenorrhea, anemia, angioedema, anisocoria, apathy, aphasia, aphthous stomatitis, apnea, arthropathy, ascites, atelectasis, balanitis, bladder neoplasm, blepharitis, blepharoptosis, blindness, bradykinesia, breast hypertrophy, bronchiolitis, cardiac failure, cellulitis, cerebellar syndrome, cervicitis, chills, cholecystitis, cholelithiasis, chondrodystrophy, cognitive dysfunction, cogwheel rigidity, colitis, coma, corneal ulcer, cutaneous nodule, decreased glucose tolerance, delirium, delusions, depression of ST segment on ECG, dermal ulcer, drug dependence, dry mucous membranes, dysarthria, dysautonomia, dysgeusia, dyskinesia, dysmenorrhea, dyspareunia, dysphagia, dystonia, dysuria, eczema, ejaculatory disorder, encephalopathy, eosinophilia, epididymitis, erythema of skin, esophageal ulcer, esophagitis, exfoliative dermatitis, exophthalmos, extraocular palsy, extrapyramidal reaction, facial pain, gastritis, gastrointestinal hemorrhage, glomerulonephritis, glycosuria, granuloma, Guillain-Barre syndrome, gynecomastia, hallucination, hangover effect, heavy menstrual bleeding, hematuria, hemophthalmos, hiccups, hirsutism, hostility, hypalgesia, hyperacusis, hyperalgesia, hyperesthesia, hyperkinetic muscle activity, hypochromic anemia, hypokinesia, hypoprothrombinemia, hypotonia, impaired consciousness, increased libido, increased neutrophils, increased serum lipase, intracranial hypertension, iritis, irritability, joint stiffness, keratitis, keratoconjunctivitis, lactation (females), laryngismus, leukocytosis, leukopenia, leukorrhea, lichenoid dermatitis, local inflammation (coccydynia), lymphadenopathy, malaise, manic reaction, melanosis, melena, miosis, mydriasis, myelofibrosis, myoclonus, nail disease, neck stiffness, nephritis, nephrolithiasis, neuralgia, nocturnal amblyopia, nonimmune anaphylaxis, nonthrombocytopenic purpura, oliguria, ophthalmoplegia, optic atrophy, oral mucosa ulcer, oral paresthesia, orthostatic hypotension, ovarian disease, palpitations, pancreatitis, papilledema, paranoid ideation, pelvic pain, periodontal abscess, periorbital edema, peripheral neuritis, personality disorder, petechial rash, photophobia, polycythemia, proteinuria, psychomotor disturbance, psychotic depression, pulmonary edema, pulmonary fibrosis, purpuric rash, pustular rash, pyelonephritis, rectal hemorrhage, respiratory depression (FDA Safety Alert, Dec 19, 2019), retinal edema, retinal vascular disease, retroperitoneal fibrosis, rhabdomyolysis, sciatica, schizophrenia, self-inflicted intentional injury, severe thrombocytopenia, shock, skin atrophy, skin blister, skin necrosis, skin photosensitivity, skin rash, sleep disorder, Stevens-Johnson syndrome, subcutaneous nodule, syncope, tachycardia, thrombocythemia, thrombophlebitis, tongue edema, torticollis, trismus, urate crystalluria, urinary retention, urine abnormality, urticaria, uterine hemorrhage, uveitis, ventricular fibrillation, vesiculobullous dermatitis, wheezing, xeroderma, xerophthalmia, yawning
* See Cautions in AHFS Essentials for additional information.
Allergy and Idiosyncratic Reactions
Metabolism/Transport Effects
None known.
Drug Interactions Open Interactions
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy
Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. Risk C: Monitor therapy
Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Risk X: Avoid combination
Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Risk D: Consider therapy modification
Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy
Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification
Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Cannabis: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification
Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy
Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Risk C: Monitor therapy
Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk D: Consider therapy modification
Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Risk D: Consider therapy modification
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy
Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification
Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk C: Monitor therapy
Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions. Monitor anticonvulsant concentrations and treatment response closely with concurrent use. Risk D: Consider therapy modification
Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Risk D: Consider therapy modification
MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy
Mianserin: May diminish the therapeutic effect of Anticonvulsants. Risk C: Monitor therapy
Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification
Orlistat: May decrease the serum concentration of Anticonvulsants. Risk C: Monitor therapy
Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination
Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification
Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination
Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Risk D: Consider therapy modification
Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy
Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy
ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy
Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy
Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor therapy
Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Risk D: Consider therapy modification
Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification
Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination
Thiazolidinediones: Pregabalin may enhance the fluid-retaining effect of Thiazolidinediones. Risk C: Monitor therapy
Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification
Food Interactions
Extended release: Bioavailability is reduced if taken on an empty stomach. The AUC is approximately 30% lower when fasting relative to following an evening meal. Management: Administer after evening meal.
Monitoring Parameters
Measures of efficacy (pain intensity/seizure frequency); degree of sedation; symptoms of myopathy; creatine kinase (as clinically indicated); symptoms of ocular disturbance; weight gain/edema; skin integrity (in patients with diabetes); signs and symptoms of suicidality (eg, suicidal thoughts, anxiety, depression, behavioral changes); platelet count (as clinically indicated)
Advanced Practitioners Physical Assessment/Monitoring
Obtain creatine kinase and platelet count as clinically indicated. Obtain periodic renal function tests; dosage adjustment may be needed. Assess for history of diabetes, cardiovascular disease, and use of ACE inhibitors. Assess patients for history of substance abuse; potential for drug dependency. Taper dose prior to discontinuation.
Nursing Physical Assessment/Monitoring
Check ordered labs and report any abnormalities. Monitor weight; educate patients to report significant or sudden weight gain. Monitor for angioedema. May cause drowsiness; educate patients to be cautious in performing tasks that require mental alertness and caution use while driving or operating hazardous machinery. Monitor for and educate patients to report any signs and symptoms of suicidal ideation, muscle pain, muscle tenderness, muscle weakness, and visual disturbances. Educate patients about administration based on rationale for administration and dosage form. Educate patient on potential of drug for abuse, stress the need to keep medication secured in the home. If treating seizures, observe and teach patients seizure precautions.
Controlled Substance
C-V
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, Oral:
Lyrica: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg [contains corn starch]
Generic: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
Solution, Oral:
Lyrica: 20 mg/mL (473 mL) [contains methylparaben, propylparaben]
Generic: 20 mg/mL (473 mL)
Tablet Extended Release 24 Hour, Oral:
Lyrica CR: 82.5 mg, 165 mg, 330 mg
Dosage Forms: Canada
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, Oral:
Lyrica: 25 mg, 50 mg, 75 mg, 150 mg, 225 mg, 300 mg
Generic: 25 mg, 50 mg, 75 mg, 150 mg, 225 mg, 300 mg
Anatomic Therapeutic Chemical (ATC) Classification
Generic Available (US)
May be product dependent
Pricing: US
Capsules (Lyrica Oral)
25 mg (per each): $9.82
50 mg (per each): $9.82
75 mg (per each): $9.82
100 mg (per each): $9.82
150 mg (per each): $9.82
200 mg (per each): $9.82
225 mg (per each): $9.82
300 mg (per each): $9.82
Capsules (Pregabalin Oral)
25 mg (per each): $2.80 - $8.90
50 mg (per each): $2.80 - $8.90
75 mg (per each): $2.80 - $8.90
100 mg (per each): $2.80 - $8.90
150 mg (per each): $2.80 - $8.90
200 mg (per each): $2.80 - $8.90
225 mg (per each): $2.80 - $8.90
300 mg (per each): $2.80 - $8.90
Solution (Lyrica Oral)
20 mg/mL (per mL): $2.62
Solution (Pregabalin Oral)
20 mg/mL (per mL): $2.12 - $2.24
Tablet, 24-hour (Lyrica CR Oral)
82.5 mg (per each): $16.88
165 mg (per each): $16.88
330 mg (per each): $16.88
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Mechanism of Action
Binds to alpha-2-delta subunit of voltage-gated calcium channels within the CNS and modulates calcium influx at the nerve terminals, thereby inhibiting excitatory neurotransmitter release including glutamate, norepinephrine (noradrenaline), serotonin, dopamine, substance P, and calcitonin gene-related peptide (Gajraj 2007; McKeage 2009). Although structurally related to GABA, it does not bind to GABA or benzodiazepine receptors. Exerts antinociceptive and anticonvulsant activity. Pregabalin may also affect descending noradrenergic and serotonergic pain transmission pathways from the brainstem to the spinal cord.
Pharmacodynamics/Kinetics
Onset of action: Pain management: Effects may be noted as early as the first week of therapy.
Absorption: Extended release: AUC is approximately 30% lower when administered while fasting
Distribution: Vd: 0.5 L/kg
Protein binding: 0%
Metabolism: Negligible
Bioavailability: ≥90%
Half-life elimination:
Children ≤6 years: 3 to 4 hours
Children 7 to <17 years: 4 to 6 hours
Adult: 6.3 hours
Time to peak, plasma:
Extended release: Median: 8 hours with food (range: 5 to 12 hours)
Immediate release:
Infants ≥3 months, Children, and Adolescents <17 years: 0.5 to 2 hours fasting
Adults: Within 1.5 hours fasting; ~3 hours with food
Excretion: Urine (90% as unchanged drug; minor metabolites)
Pharmacodynamics/Kinetics: Additional Considerations
Pediatric: Clearance in pediatric patients weighing <30 kg has been observed to be 40% higher than those weighing ≥30 kg.
Geriatric: Oral clearance tends to decrease with increasing age.
Local Anesthetic/Vasoconstrictor Precautions
No information available to require special precautions
Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Xerostomia and changes in salivation (normal salivary flow resumes upon discontinuation).
Effects on Bleeding
May be associated with thrombocytopenia (3%). No information available to require routine special precautions
Related Information
Index Terms
CI-1008; S-(+)-3-isobutylgaba
FDA Approval Date
December 30, 2004
References
2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767[PubMed 30693946]
Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11(6):512-519.[PubMed 20466589]
Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621-631.[PubMed 24521108]
Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi: 10.1002/cpt.377.[PubMed 27060684]
Arnold LM, McCarberg BH, Clair AG, et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017;129(8):921-933. doi: 10.1080/00325481.2017.1384691.[PubMed 28967801]
Arnold LM, Schikler KN, Bateman L, et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46.[PubMed 27475753]
Atıs G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther. 2017;30(2). doi: 10.1111/dth.12459.[PubMed 28168835]
Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199. doi: 10.1136/bmj.d1199.[PubMed 21398351]
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. doi: 10.1177/0269881114525674.[PubMed 24713617]
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9(4):248-312. doi: 10.1080/15622970802465807.[PubMed 18949648]
Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care [published corrections appear in Int J Psychiatry Clin Pract. 2012;16(3):242; Int J Psychiatry Clin Pract. 2013;17(1):76]. Int J Psychiatry Clin Pract. 2012;16(2):77-84.[PubMed 22540422]
Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185-1215. doi: 10.1016/j.euroneuro.2017.08.430.[PubMed 28988943]
Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry. 2011;56(9):558-566.[PubMed 21959031]
Bril V, England J, Franklin GM, et al, "Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation," Neurology, 2011, 76(20):1758-65.[PubMed 21482920]
Bystritsky A. Pharmacotherapy for generalized anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 5, 2018.
Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council [published correction appears in J Pain. 2016;17(4):508-510]. J Pain. 2016;17(2):131-157. doi: 10.1016/j.jpain.2015.12.008.[PubMed 26827847]
Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update [published correction appears in Endocr Pract. 2017;23(12):1488]. Endocr Pract. 2017;23(7):869-880. doi: 10.4158/EP171828.PS.[PubMed 28703650]
Craske M, Bystritsky A. Approach to treating generalized anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 5, 2019.
Dalal S. Palliative care: Overview of pruritus and sweating. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 6, 2018.
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.[PubMed 30113379]
Eipe N, Penning J, Yazdi F, et al. Perioperative use of pregabalin for acute pain-a systematic review and meta-analysis. Pain. 2015;156(7):1284-1300. doi: 10.1097/j.pain.0000000000000173.[PubMed 25830925]
El Kenany S, El Tahan MR. Effect of preoperative pregabalin on post-caesarean delivery analgesia: a dose-response study. Int J Obstet Anesth. 2016;26:24-31.[PubMed 26718698]
Engelman E, Cateloy F. Efficacy and safety of perioperative pregabalin for post-operative pain: a meta-analysis of randomized-controlled trials. Acta Anaesthesiol Scand. 2011;55(8):927-943. doi: 10.1111/j.1399-6576.2011.02471.x.[PubMed 21707548]
Fazio SB, Yosipovitch G. Pruritus: Overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 11, 2018.
FDA Safety Alert. MedWatch. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Published December 19, 2019. Accessed December 23, 2019.
Feldman E, McCulloch D. Treatment of diabetic neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 5, 2018.
Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26(4):213-220. doi: 10.1097/YIC.0b013e32834519bd.[PubMed 21368587]
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi: 10.1016/S1474-4422(14)70251-0.[PubMed 25575710]
Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodial Int. 2017;21(1):63-71. doi: 10.1111/hdi.12455.[PubMed 27397522]
Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012;21(128):152-154.[PubMed 22822593]
Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105(6):1805-1815.[PubMed 18042886]
Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine. 2013;14(7):675-684. doi: 10.1016/j.sleep.2013.05.016.[PubMed 23859128]
Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635-643. doi: 10.5665/sleep.3558.[PubMed 24899755]
Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. Sleep Med. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.[PubMed 27448465]
Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49-55.[PubMed 27643884]
Goldenberg DL. Treatment of fibromyalgia in adults not responsive to initial therapies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 5, 2019.
Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011;26(5):243-251. doi: 10.1097/YIC.0b013e3283491fd5.[PubMed 21734588]
Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]
Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies. Eur Neuropsychopharmacol. 2014;24(1):125-132. doi: 10.1016/j.euroneuro.2013.10.015.[PubMed 24290532]
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1.[PubMed 25081580]
Kobrin SM. Uremic pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 21, 2018.
Lavand'homme PM, Roelants F. Evaluation of pregabalin as an adjuvant to patient-controlled epidural analgesia during late termination of pregnancy. Anesthesiology. 2010;113(5):1186-1191.[PubMed 20938333]
Lockwood PA, Pauer L, Scavone JM, et al. The pharmacokinetics of pregabalin in breast milk, plasma, and urine of healthy postpartum women. J Hum Lact. 2016. pii: 0890334415626148.[PubMed 26961752]
Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1 [published correction appears in J Clin Oncol. 2010;28(10):1808]. J Clin Oncol. 2010;28(4):641-647.[PubMed 19901102]
Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13(2):229-241. doi: 10.1017/S1461145709990460.[PubMed 19737439]
Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; May 2019.
Lyrica CR (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; June 2019.
Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs. 2008;68(15):2205-2223.[PubMed 18840008]
Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol. 2016;75(3):619-625.e6. doi: 10.1016/j.jaad.2016.02.1237.[PubMed 27206757]
McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26(10):883-892.[PubMed 19761281]
Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015;114(1):10-31. doi: 10.1093/bja/aeu293.[PubMed 25209095]
Mostacci B, Poluzzi E, D'Alessandro R, et al. Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. J Neurol Neurosurg Psychiatry. 2017.[PubMed 19761281]
Moulin D, Boulanger A, Clark AJ, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-335.[PubMed 25479151]
North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-1172.[PubMed 26382310]
Ohman I, De Flon P, Tomson T. Pregabalin kinetics in the neonatal period, and during lactation. Epilepsia. 2011;52 (suppl 6):249-250. Abstract p824.
Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69.[PubMed 27400984]
Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141-149.[PubMed 15206660]
Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017;88(21):2020-2025.[PubMed 28446648]
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi: 10.2337/dc16-2042.[PubMed 27999003]
Reid R, Abramson BL, Blake J, et al; Menopause and Osteoporosis Working Group; Society of Obstetricians and Gynaecologists of Canada. Managing menopause. J Obstet Gynaecol Can. 2014;36(9):830-838.[PubMed 25222364]
Santen R, Loprinzi C, Casper R. Menopausal hot flashes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 10, 2019.
Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton). 2012;17(8):710-717. doi: 10.1111/j.1440-1797.2012.01655.x.[PubMed 22909343]
Stein M. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 5, 2018.
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi: 10.1210/jc.2015-2236[PubMed 26444994]
Tietze KJ. Sedative-analgesic medications in critically ill adults: properties, dosage regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 14, 2019.
Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563-581. doi: 10.2340/00015555-1400.[PubMed 22790094]
Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults. Neurology. 2016;87(24):2585-2593. doi: 10.1212/WNL.0000000000003388[PubMed 27856776]
Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology 2016;86(24):2251-2257[PubMed 27194385]
Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579-588. doi: 10.1007/s00415-013-7239-x.[PubMed 24449062]
Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016;149(3):639-648. doi: 10.1378/chest.15-1271.[PubMed 26447687]
Vestita M, Cerbone L, Calista D. Brachioradial pruritus in a 47-year-old woman treated with pregabalin. G Ital Dermatol Venereol. 2016;151(6):727-728.[PubMed 27824228]
Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. Int Urol Nephrol. 2015;47(1):161-167. doi: 10.1007/s11255-014-0795-x.[PubMed 25099523]
Zhang J, Ho KY, Wang Y. Efficacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth. 2011;106(4):454-462. doi: 10.1093/bja/aer027.[PubMed 21357616]
Brand Names: International
Algecia (NL); Andogablin (EG); Axual (AR); Balinozar (EG); Brieka (CZ, IE); Egzysta (CZ, VN); Erclany (CZ); Funxion (PH); Gabarol (BD); Gabi (PH); Gabica (PH, PK, VN); Gablin (PH); Gabrika (LB); Galica (LB); Gavin (AR); Gloryca (VN); Innikra (ZW); Kemirica (EG); Labalin (ID); Lalaca (KR); Lecaent (GB); Leptica (ID); Ligaba (PH); Linefor (NL); Lingabat (NL); Lipapyn (ZW); Lirystad (VN); Lybalin (TH); Lyrica (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN, ZW); Lyrigab (LK); Lyzalon (AU); Martesia (EC); Neo Gaba (BH); Neogabin (UA); Nervax (BH, LB); Nervica (TH); Neufar (ID); Neugalin (BD); Neuroccord (AU); Neurocover-PG (KR); Neurovan (BD); Neuroz (PH); Neurum (CL, EC); Nomathic (ID); PGB (ID); Plenica (LB); Prebarin (TH); Prega 150 (ZW); Pregaba (ZW); Pregabadin (PY); Pregadex (BH); Pregalex (EC); Pregalin (KR); Pregaredi (SG); Pregasafe-150 (TZ); Pregasafe-75 (TZ); Pregax (LK); Pregeb (PH); Preneurin (PH); Prepentin (VN); Prex (BH); Provelyn (ID); Regab (BD); Rewisca (GB, MY); Silica (KR); Toprelin (TH); Vexer (LK, PH); Xablin (BD); Zeegap (LK); Zyzyx (PH)
Last Updated 2/27/20